607 related articles for article (PubMed ID: 18616513)
41. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
42. [Expression of trophoblast invasion related genes mRNA and protein in human placenta in preeclampsia].
Zhang H; Lin QD; Qiao C
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):509-13. PubMed ID: 17083831
[TBL] [Abstract][Full Text] [Related]
43. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
45. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
46. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
47. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
Cai W; Song JD
Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
[TBL] [Abstract][Full Text] [Related]
48. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
49. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
50. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.
Sakata K; Satoh M; Someya M; Asanuma H; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
Cancer; 2004 Jan; 100(2):356-65. PubMed ID: 14716772
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
52. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Kyllönen H; Pasanen AK; Kuittinen O; Haapasaari KM; Turpeenniemi-Hujanen T
Leuk Lymphoma; 2009 Aug; 50(8):1301-7. PubMed ID: 19811332
[TBL] [Abstract][Full Text] [Related]
53. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
[TBL] [Abstract][Full Text] [Related]
54. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
55. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
56. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
57. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
60. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]